Document Detail

Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib.
MedLine Citation:
PMID:  18519516     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Dasatinib is a multitargeted inhibitor of ABL, the SRC family, and other tyrosine kinases. We sought to evaluate the effects of this drug on cell proliferation, centrosomes, mitotic spindles, and cell cycle progression in vitro and in vivo. DESIGN AND METHODS: Human dermal fibroblasts, Chinese hamster cells, human osteosarcoma cells, and blood and bone marrow mononuclear cells from 32 patients with chronic myeloid leukemia, gastrointestinal stromal tumor, and systemic mastocytosis as well as from six healthy individuals were investigated. The effects of dasatinib were compared with those of the ABL inhibitors imatinib and nilotinib, the SRC inhibitor PP2, and the ABL/LYN inhibitor INNO-406. RESULTS: Dasatinib induced G(1) phase arrest in all cell lines and this was associated with a decline in cyclin D1 levels. In vitro, centrosomal aberrations, a decrease of mitotic spindles, and G(1) phase arrest were observed. In patients, centrosome alterations were found in a median of 17% (range, 10-22%) of cells with a decrease of spindles in 8/18 patients. In comparison, imatinib, nilotinib and PP2 led to centrosome aberrations without G(1) phase arrest. INNO-406 was associated with centrosome aberrations and cell cycle arrest in G(1) phase. CONCLUSIONS: Dasatinib blocks the G(1)/S transition and inhibits cell growth. It induces centrosomal aberrations and a decrease of mitotic spindles. The effects suggest an involvement of SRC and ABL inhibition.
Alice Fabarius; Michelle Giehl; Blanka Rebacz; Alwin Krämer; Oliver Frank; Claudia Haferlach; Peter Duesberg; Rüdiger Hehlmann; Wolfgang Seifarth; Andreas Hochhaus
Related Documents :
16118246 - Quantification of microtubule nucleation, growth and dynamics in wound-edge cells.
11804606 - Role of mitotic motors, dynein and kinesin, in the induction of abnormal centrosome int...
10098646 - Inflammatory pseudotumor in a cat with cutaneous mycobacteriosis.
21052096 - A novel microtubule-modulating noscapinoid triggers apoptosis by inducing spindle multi...
18447926 - Hypoxia-inducible factor-1alpha is a critical mediator of hypoxia induced apoptosis in ...
23416106 - Interaction of 5-androstene-3β, 17β-diol and 5α-androstane-3β, 17β-diol with estro...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-06-02
Journal Detail:
Title:  Haematologica     Volume:  93     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-08-01     Completed Date:  2008-10-09     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  1145-54     Citation Subset:  IM    
III. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Wiesbadener Strasse 7-11, 68305 Mannheim, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology*
Bone Marrow Cells / drug effects,  pathology
CHO Cells
Cell Division / drug effects
Cell Line, Tumor
Centrosome / drug effects*
Fibroblasts / physiology*
G1 Phase / drug effects,  genetics*
Genes, abl / drug effects*
Genes, src / drug effects*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood,  drug therapy,  pathology
Piperazines / pharmacology*,  therapeutic use
Pyrimidines / pharmacology*,  therapeutic use
Skin Physiological Phenomena
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating a...
Next Document:  Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia ...